Lentiviral Vector (LVV)

Lot Release Testing for
LVV Vector Products

A Comprehensive Testing Panel for Confident Release

Lentiviral vectors (LVVs) have become a cornerstone of modern gene and cell therapies, enabling stable gene transfer for transformative treatments. As these advanced therapeutics move from development to commercialization, robust and reliable lot release testing is critical to ensure patient safety, product consistency, and regulatory compliance. This flyer includes many of the assays needed for lot release and characterization with specific drugs and production processes dictating which are chosen to support a final testing strategy.

Full Assay Name
BH
DS
DP
Stability
Test Code
Minimum Sample Requirements
TAT (days)
Safety
Isolator Sterility Testing by Direct Inoculation USP<71> (GMP) – (Up to 100mL TA or 20 Vials)
✅
✅
✅
3000004994
Per USP guidelines
21
Bacteriostasis and Fungistasis (Direct Method) (GMP)1
✅
✅
3000004996
Varies depending on fill/volume
21
Analysis of Bacterial Endotoxin Contamination Using Endosafe® nexgen-PTS™ (GMP)
✅
✅
3000005222
1 mL
7
Analysis of Bacterial Endotoxin Contamination Using the Endosafe® nexgen-PTS™ – Test for Interfering Factors (GMP)
✅
✅
3000005260
1 mL
14
EP, JP, and USP Mycoplasma Detection (GMP)
✅
3000005147
1×15 mL & 1e6 cells/mL
35
EP, JP, and USP Mycoplasma Detection with Mycoplasmastasis (GMP)
✅
3000007121
1×45 mL & 1e6 cells/mL
35
Mycoplasma DNA Detection by MycoSEQ Plus using TaqMan Technology – Cell + Suspension (GMP)
✅
3000004752
30 mL cell suspension
10
Microbiological Examination: Microbial Enumeration Test according to USP<61> (GMP)
✅
3000005066
2x specification
14
Microbiological Examination of Non-sterile products: Microbial Enumeration Test Suitability <61> (GMP)
✅
3000005068
8x routine
21
9 CFR Bovine Viruses Detection in Bovine Serum or Other Products – 21 day (GMP)
✅
3000007314
1×500 mL serum or 2×8 mL cell lysate
31
9 CFR Porcine Viruses Detection – 21 day (GMP)
✅
3000007387
1×500 mL serum or 2×8 mL cell lysate
31
In Vitro Assay for Adventitious Viral Contaminants: MRC-5, VERO, and HEK Cells (Extended Duration) with Hemadsorption and Hemagglutination Endpoints (GMP)
✅
3000005475
2×6 mL at 1e7 cells/mL
35
Mycobacterium Tuberculosis DNA Detection by qPCR (GMP)
✅
3000005638
1e7 cells frozen
9
RCL Assay: Co-cultivation of Test Article Cells with C8166 Cells (GMP)
✅
3000007915
1% or 1e8 cells (whichever is less)
56
RCL Assay: Amplification of Test Article Supernatant with C8166 Cells – Large Scale (5% of total supernatant, 200 mL to 300 mL) (GMP)
✅
3000007492
5% or 300 mL of supernatant (whichever is less)
56
Strength
Lentiviral Infectious Titer Assay with a qPCR Endpoint (GMP)
✅
✅
✅
✅
3000005157
3×0.5 mL
35
Lentivirus Titer Determination by p24 ELISA (GMP)
✅
✅
✅
3000005164
1 mL
21
Lentivirus Titer Determination by p30 ELISA (GMP)
✅
✅
✅
Custom
Varies
TBD
Potency
Product Specific Assessment Indicative of MOA (GMP)
✅
✅
✅
Custom
Varies
TBD
Quality
Dynamic Light Scattering Analysis for Determination of Particle Size of Virus Lots (GMP)
✅
✅
3000007812
0.1 mL
8
Determination of Appearance According to the USP (GMP)
✅
✅
3000005469
2 mL
8
USP<697> and EP 2.9.17 Determination of Extractable Volume in Containers (GMP)
✅
✅
3000005712
Varies2
14
USP<785> Determination of Osmolality (GMP)
✅
✅
3000007458
0.1 mL
8
USP <791> Determination of the pH and Appearance (GMP)
✅
✅
3000004853
1 mL
8
EU Appearance of Liquids (GMP)
✅
✅
3000005395
10 mL
14
Identity
High Throughput Sequencing Using Ion Torrent Genexus (GMP)
✅
3000004999
Reference sequence, >/= 2e10 GC
18
Purity
Immunoenzymetric Assay for the Determination of HEK 293 Host Cell Proteins (GMP)
✅
3000004873
0.5 mL
21
Immunological Detection of Benzonase Endonuclease (GMP)
✅
3000004866
1 mL
8
Determination of Residual Bovine Serum Albumin (BSA) by ELISA using Bethyl ELISA Kit E11-113 (GMP)
✅
3000004586
0.3 mL
21
Quantitation of Residual DNA Using PrepSEQ™ and TaqMan® Technology by qPCR (GMP) – 7 Targets 18S (102bp, 200bp, 254bp, 401bp-amplicons) + E1A + SV40 + E1B
✅
Varies
1e7 cells frozen
TBD

1 Ingress Study may need to be conducted if the container has not been previously validated.

2 1 container if contents are 10 mL or more; 3 containers if volume is between 3 mL and <10mL; 5 containers if volume is <3 mL.

Unique Challenges for LVV

  • Testing LVVs presents a unique set of scientific and operational challenges that are more pronounced than for AAV and many other viral vectors, largely due to LVV’s retroviral biology and reliance on functional infectivity. Unlike AAV, LVVs integrate into the host genome and carry a theoretical risk of generating replication-competent lentivirus (RCL), requiring extended, highly scrutinized cell-based amplification assays.

  • Lot release decisions also depend heavily on infectious titer—a variable, cell-based assay that is sensitive to envelope incorporation, handling, and stability—rather than genome titer alone. In addition, the multi-plasmid production system introduces recombination and residual DNA complexities that demand careful monitoring. Together, these factors make LVV lot release more biologically driven, safety-focused, and operationally time-sensitive than many other viral vector platforms.

Why Minaris?

With decades of experience in viral safety, retrovirus detection, and cell-based assay systems, Minaris is uniquely positioned to manage the biological variability and extended timelines associated with LVV testing. Our expertise in designing, validating, and executing amplification-based RCL assays ensures rigorous safety evaluation aligned with global regulatory standards. At the same time, our proficiency in cell-based potency and infectivity assays supports consistent, reproducible results for one of the most critical release attributes.

Minaris Advanced Testing combines technical depth with operational discipline, offering coordinated testing programs that integrate safety, potency, identity, and impurity testing into a streamlined release strategy. Our established quality systems, experienced scientific teams, and robust assay platforms enable comprehensive, predictable, and reliable lot release testing services tailored specifically to the demands of lentiviral vector products. A structured testing panel — built around LVV-specific challenges — enables reliable lot disposition, regulatory confidence, and ultimately, safe delivery of life-changing therapies to patients.

Get in Touch With Our Team Today

Ready to discuss your LVV lot release testing needs? Our team is here to help.

Contact Us